Marie Thibault
Stock Analyst at BTIG
(3.89)
# 691
Out of 4,761 analysts
71
Total ratings
52.86%
Success rate
10.28%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EMBC Embecta | Upgrades: Buy | $26 | $14.10 | +84.40% | 2 | Nov 27, 2024 | |
| PODD Insulet | Maintains: Buy | $260 → $270 | $282.80 | -4.53% | 4 | Nov 8, 2024 | |
| MASI Masimo | Maintains: Buy | $166 → $170 | $169.96 | +0.02% | 3 | Oct 14, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $62 → $65 | $33.43 | +94.44% | 8 | Oct 14, 2024 | |
| BSX Boston Scientific | Maintains: Buy | $84 → $93 | $104.49 | -11.00% | 7 | Oct 14, 2024 | |
| HAE Haemonetics | Initiates: Buy | $112 | $63.02 | +77.72% | 1 | Sep 10, 2024 | |
| ATRC AtriCure | Maintains: Buy | $58 → $53 | $38.39 | +38.06% | 4 | Jul 31, 2024 | |
| DXCM DexCom | Maintains: Buy | $156 → $120 | $88.78 | +35.17% | 7 | Jul 26, 2024 | |
| XAIR Beyond Air | Downgrades: Neutral | n/a | $0.35 | - | 2 | Jun 25, 2024 | |
| VERO Venus Concept | Downgrades: Neutral | n/a | $0.31 | - | 3 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $20 | $14.88 | +34.41% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $140 | $119.44 | +17.21% | 7 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $2.70 | +11.11% | 3 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $125 | $134.92 | -7.35% | 11 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $2.11 | +231.75% | 1 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.13 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.96 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $179.93 | -96.67% | 1 | Apr 9, 2020 |
Embecta
Nov 27, 2024
Upgrades: Buy
Price Target: $26
Current: $14.10
Upside: +84.40%
Insulet
Nov 8, 2024
Maintains: Buy
Price Target: $260 → $270
Current: $282.80
Upside: -4.53%
Masimo
Oct 14, 2024
Maintains: Buy
Price Target: $166 → $170
Current: $169.96
Upside: +0.02%
Establishment Labs Holdings
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $33.43
Upside: +94.44%
Boston Scientific
Oct 14, 2024
Maintains: Buy
Price Target: $84 → $93
Current: $104.49
Upside: -11.00%
Haemonetics
Sep 10, 2024
Initiates: Buy
Price Target: $112
Current: $63.02
Upside: +77.72%
AtriCure
Jul 31, 2024
Maintains: Buy
Price Target: $58 → $53
Current: $38.39
Upside: +38.06%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $156 → $120
Current: $88.78
Upside: +35.17%
Beyond Air
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.35
Upside: -
Venus Concept
Oct 6, 2023
Downgrades: Neutral
Price Target: n/a
Current: $0.31
Upside: -
Aug 16, 2023
Maintains: Buy
Price Target: $19 → $20
Current: $14.88
Upside: +34.41%
Jun 8, 2023
Maintains: Buy
Price Target: $165 → $140
Current: $119.44
Upside: +17.21%
Mar 29, 2023
Maintains: Buy
Price Target: $4 → $3
Current: $2.70
Upside: +11.11%
Jan 26, 2023
Maintains: Buy
Price Target: $120 → $125
Current: $134.92
Upside: -7.35%
Jun 24, 2022
Maintains: Buy
Price Target: $9 → $7
Current: $2.11
Upside: +231.75%
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $4.13
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.96
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $179.93
Upside: -96.67%